Who
Richard S. Levy
Director
Company insider
Files Form 4 as: Director, Kiniksa Pharmaceuticals International; Director, Kodiak Sciences; Director, Madrigal Pharmaceuticals; Director, Protara Therapeutics; Director, Constellation Pharmaceuticals; EVP, Chief Drug Dev Officer, Incyte.
In numbers
- Trades disclosed
- 351
- Buys
- 6
- Sells
- 40
- Bought
- $318K
- Sold
- $73.7M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 27 Jan 2009
- Last trade
- 1 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —403 | filing |
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —403 at $0.00 | filing |
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —403 at $0.00 | filing |
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —403 at $0.00 | filing |
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —403 at $0.00 | filing |
| 1 Aug 2026filed 4 Aug 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —403 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,731 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,731 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,799 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,799 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Richard S. Levy; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.